Status and phase
Conditions
Treatments
About
This study is a prospective, randomized, open-label, multicenter phase IIB trial in order to determine time to progression of the combination therapy sorafenib plus doxorubicin against standard-of-care sorafenib in advanced HCC not amenable to non-systemic treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Excluded therapies and medications, previous and concomitant:
Primary purpose
Allocation
Interventional model
Masking
170 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal